Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | IMW 2019: what to expect!

Steven Treon • 17 May 2019
COMy 2019
Amyloidosis Multiple Myeloma Rare Diseases

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, gives us exciting information on what to expect at the 2019 International Myeloma Workshop (IMW), which is being held on the 12-15 September in Boston. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Steven Treon

The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia 1:18
The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia
Steven Treon • 19 Jun 2025
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis 1:13
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis
Steven Treon • 19 Jun 2025
Exciting developments in Waldenström’s macroglobulinemia: insights from a ‘Meet the Expert’ session 2:56
Exciting developments in Waldenström’s macroglobulinemia: insights from a ‘Meet the Expert’ session
Steven Treon • 19 Jun 2025
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients 1:49
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients
Steven Treon • 19 Jun 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals